Microsaic Systems plc MSYS jointly publishes bioprocessing data with MIT
05 Março 2019 - 4:02AM
RNS Non-Regulatory
TIDMMSYS
Microsaic Systems plc
05 March 2019
5 March 2019
Microsaic Systems plc
("Microsaic" or the "Company")
Microsaic jointly publishes bioprocessing data with MIT
Microsaic Systems plc (AIM: MSYS), the developer of point of
need mass spectrometry ("MS") instruments, announces its joint
publication with Massachusetts Institute of Technology ("MIT")
"Using MS for point of need bioprocessing".
Today, Microsaic and MIT will be showcasing the latest results
of their collaboration in advancing point of need bioprocessing
analysis, at the International Foundation of Process Analytical
Chemistry ("IFPAC") 2019, in Washington, DC.
This latest phase in the collaboration looks at the effects of
storage and time conditions, feeding strategies, and media type on
protein quality, and compares frozen and fresh cell cultures. The
new demands of modern bioprocessing (for the manufacture of
biologic drugs, or "biologics") together with the implementation of
Quality by Design ("QbD") and Process Analytical Technology ("PAT")
methods require a deeper understanding of these processes. MS is
well placed to provide the information rich data required.
Glenn Tracey, CEO of Microsaic, commented, "Traditional mass
spectrometers are large, expensive, and require operation by
specialists in centralised laboratories. Integrated real-time MS,
decentralized and at the point-of-need, could provide important
process information quickly and at a reduced cost. Microsaic is
working closely with MIT, at the feasibility of using deployable
and compact mass spectrometry for the direct analysis of upstream
cell cultures to show a compelling user scenario for our
technology."
Biologic drugs represented eight out of ten top selling drugs in
2017, and estimated revenues will reach over $380Bn by 2024. The
Directors believe that the total market for bioprocessing equipment
in the pharmaceutical industry is currently in the region of
$15Bn.
Recently, Microsaic announced its innovative new product, the
MiD(R) ProteinID, which the Analytical Scientist recognised as one
of the top innovative products of 2018.
Enquiries:
Microsaic Systems plc
Glenn Tracey, CEO
Bevan Metcalf, FD +44 (0) 1483 751 577
N+1 Singer (Nominated Adviser &
Broker)
Shaun Dobson / George Tzimas (Corporate
Finance)
Tom Salvesen (Corporate Broking) +44 (0)20 7496 3000
IFC Advisory Ltd (Financial PR)
Graham Herring
Heather Armstrong
Florence Chandler +44 (0)20 3934 6630
About Microsaic Systems
Microsaic Systems plc (AIM: MSYS) is a high technology company
developing chip-based, bench-top and point-of-analysis mass
spectrometry ("MS") instruments that are designed to improve the
efficiency of pharmaceutical R&D and manufacturing. The Company
works with established global life science companies to co-develop
new solutions to improve productivity in the development of small
molecule and novel biologic (peptides, antibodies) medicines. MS is
a powerful method of analysis to enable earlier decision making
relating to product identification, purity and bioactivity, and is
the analytical technique of choice for biochemists across many
industry sectors.
The Microsaic's compact MiD(R) MS systems retain the
functionality of larger conventional MS systems, while being easier
to use by non-specialists, and consume less energy and have lower
running costs. For more information, please go to
www.microsaic.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFMGGFVDKGLZM
(END) Dow Jones Newswires
March 05, 2019 02:02 ET (07:02 GMT)
Microsaic Systems (LSE:MSYS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Microsaic Systems (LSE:MSYS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024